本文選題：原位種植性肝癌 + 血管內(nèi)皮生長因子��； 參考：《中山大學(xué)學(xué)報(bào)(醫(yī)學(xué)科學(xué)版)》2017年03期

【摘要】：【目的】探索sorafenib(索拉非尼)在不同干預(yù)時(shí)機(jī)中對(duì)血管內(nèi)皮生長因子(VEGF)促瘤效應(yīng)的抑制作用。【方法】將50只SD大鼠肝臟接種Wakler256腫瘤細(xì)胞形成的裸鼠皮下瘤塊,10 d后行MR掃描,選取建模成功的40只SD大鼠隨機(jī)分成4組,每組10只:A組,對(duì)照組,僅注射VEGF;B組,sorafenib先于VEGF 72 h導(dǎo)入組;C組,sorafenib與VEGF同時(shí)導(dǎo)入組;D組,sorafenib后于VEGF 72 h導(dǎo)入組。觀察并比較4組實(shí)驗(yàn)動(dòng)物腫瘤的生長及中位生存時(shí)間。待實(shí)驗(yàn)動(dòng)物死亡后,采用免疫組織化學(xué)法檢測(cè)各組大鼠肝腫瘤的VEGF的表達(dá)�！窘Y(jié)果】服用sorafenib 10 d后,MR顯示各組大鼠肝臟腫瘤明顯增大,sorafenib組腫瘤大小小于對(duì)照組(5.40 cm),具有統(tǒng)計(jì)學(xué)意義(P0.05)。四組實(shí)驗(yàn)動(dòng)物中位生存時(shí)間分別是(19.6±1.8)d、(31.2±7.0)d、(27.4±4.9)d、(26.5±4.6)d。服用sorafenib組大鼠生存時(shí)間明顯長于對(duì)照組(P0.05)。將死亡實(shí)驗(yàn)大鼠進(jìn)行HE染色及免疫組織化學(xué)檢查,四組實(shí)驗(yàn)動(dòng)物的VEGF值分別為88.3±13.6、42.8±8.0、71.9±15.7、73.6±13.7,sorafenib組與對(duì)照組數(shù)值差異具有明顯統(tǒng)計(jì)學(xué)意義(P0.05),且不同sorafenib組之間數(shù)值差異較大。【結(jié)論】Sorafenib能延長肝腫瘤大鼠的生存時(shí)間,減少腫瘤血管生成。Sorafenib服用時(shí)間早于VEGF一過性升高前的生存獲益明顯好于VEGF升高后服用。
[Abstract]:[objective] to investigate the inhibitory effect of sorafenibil on vascular endothelial growth factor (VEGF) in different intervention time. [methods] 50 SD rats were inoculated with subcutaneous tumor cells of Wakler256 tumor cells in nude mice for 10 days. Forty SD rats were randomly divided into 4 groups, 10 rats in each group and 10 rats in control group. Only group VEGFN B was injected with sorafenib before VEGF 72 h in group C and group C was introduced with VEGF at the same time as group D and then group D was injected with sorafenib at 72 h before VEGF was introduced at 72 h. The growth and median survival time of tumor in 4 groups were observed and compared. After the death of the experimental animal, Immunohistochemical method was used to detect the expression of sorafenib in the liver tumors of rats in each group. [results] after 10 days of administration of sorafenib, Mr showed that the tumor size of the group was significantly larger than that of the control group (5.40 cm ~ (-1), which had statistical significance (P 0.05). The median survival time of the experimental animals in the four groups was 19.6 鹵1.8g / d, 31.2 鹵7.0g / d, 27.4 鹵4.9g / d, 26.5 鹵4.6 / d, respectively. The survival time of sorafenib group was longer than that of control group (P 0.05). The death rats were stained with HE and immunohistochemistry. The VEGFvalues of the experimental animals in the four groups were 88.3 鹵13.6 鹵42.8 鹵8.0 鹵71.9 鹵15.77.73.6 鹵13.7 respectively, and there were significant differences between the sorafenib groups and the control group. [conclusion] Sorafenib can prolong the survival time of the rats with liver tumor, and the difference is significant among the four groups. [conclusion] Sorafenib can prolong the survival time of the rats with liver tumor. The survival benefit of decreasing tumor angiogenesis. Sorafenib was significantly better than that of VEGF.
【作者單位】： 中山大學(xué)附屬第一醫(yī)院放射介入科;
【基金】：吳階平醫(yī)學(xué)基金(320.6750.14800)
【分類號(hào)】：R735.7

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 逯華;陳日新;;多激酶抑制藥索拉非尼的研究進(jìn)展[J];右江民族醫(yī)學(xué)院學(xué)報(bào);2008年04期

2 祁慧薇;范理宏;;索拉非尼抑制人非小細(xì)胞肺癌細(xì)胞的增殖并誘導(dǎo)其凋亡[J];腫瘤;2011年12期

3 王玉蘭;林挺巖;陳湘琦;;索拉非尼抗腫瘤作用的研究現(xiàn)狀與進(jìn)展[J];中國醫(yī)藥指南;2011年33期

4 楊柳青;秦叔逵;龔新雷;劉秀峰;華海清;夏兆s，

本文編號(hào)：2016820